Verrica Pharmaceuticals Inc.
NASDAQ:VRCABiotechnology
-$0.02 today
- Market cap
- $53.94M
- Beta
- 1.49
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$1.67
Volume 0.10M
Average 0.08M
VRCA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Verrica Pharmaceuticals Inc.NASDAQ: VRCA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $3.86M rose 69.0% year over year, ahead of the +13.7% change in trailing-twelve-month research & development. Sequentially, it rose 53.2% from the prior quarter. Over 3 fiscal years it compounded at -10.1% a year.
Context
- Research & development amounted to 24.9% of revenue in FY2025, down 131.6 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +69.0% holds above the trailing-twelve-month pace of +13.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 8.86M USD
- Year-over-year change
- -25.2%
- 4-year CAGR
- -13.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.86M | -25.2% |
| FY2024 | 2024-12-31 | 11.84M | -41.7% |
| FY2023 | 2023-12-31 | 20.3M | +66.4% |
| FY2022 | 2022-12-31 | 12.2M | -23.4% |
| FY2021 | 2021-12-31 | 15.93M | — |
Research & Development vs competitors
How VRCA compares with its peers on the latest reported figures
- VRCA's LTM Mar 2026 research & development of $10.43M is the lowest of the 5 companies compared; the peer median is $33.13M.
- Its year-over-year change of +13.7% is the 2nd highest of 5, against a peer median of -25.2%.
- Research & development amounts to 28.1% of revenue for VRCA, versus a peer median of 28.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $49.22M | +63.5% | -1.9% | — | |
| LTM Mar 2026 | $42.44M | -21.4% | +6.5% | — | |
| LTM Mar 2026 | $23.82M | -28.9% | -5.7% | — | |
| LTM Mar 2026 | $15.25M | -66.4% | -18.8% | 28.4% | |
| LTM Mar 2026 | $10.43M | +13.7% | -10.1% | 28.1% | |
| Peer median (excluding VRCA) | $33.13M | -25.2% | -3.8% | 28.4% | |
Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12M | 9.03M | 5.12M | 7.57M | 35.58M |
| Cost of Revenue | 472K | 725K | 746K | 2.74M | 3.44M |
| Gross Profit | 11.53M | 8.31M | 4.38M | 4.83M | 32.14M |
| Gross Margin | 96.1% | 92.0% | 85.4% | 63.8% | 90.3% |
| Research & Development | 15.93M | 12.2M | 20.3M | 11.84M | 8.86M |
| Selling, General & Admin | 26.98M | 17.41M | 47.31M | 58.82M | 35.22M |
| Operating Expenses | 42.44M | 29.6M | 70.14M | 70.75M | 44.08M |
| Depreciation & Amortization | 472K | 718K | 836K | 1.27M | 781K |
| EBITDA | (30.31M) | (21.6M) | (62.2M) | (65.9M) | (9.36M) |
| EBITDA Margin | -252.6% | -239.1% | -1213.8% | -871.0% | -26.3% |
| Operating Income | (30.91M) | (21.3M) | (65.76M) | (65.92M) | (11.94M) |
| Operating Margin | -257.6% | -235.8% | -1283.4% | -871.3% | -33.6% |
| Interest Income | 123K | 476K | 2.74M | 1.42M | 929K |
| Interest Expense | 4.3M | 2.17M | 3.96M | 9.41M | 7.74M |
| Other Income / Expenses | (4.17M) | (3.19M) | (1.24M) | (10.66M) | (5.95M) |
| Income Before Tax | (35.08M) | (24.49M) | (67M) | (76.58M) | (17.89M) |
| Pre-Tax Margin | -292.3% | -271.1% | -1307.5% | -1012.1% | -50.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.08M) | (24.49M) | (67M) | (76.58M) | (17.89M) |
| Net Margin | -292.3% | -271.1% | -1307.5% | -1012.1% | -50.3% |
| EPS (Basic) | (12.97) | (7.17) | (14.78) | (14.78) | (1.68) |
| EPS (Diluted) | (12.97) | (7.17) | (14.78) | (14.78) | (1.68) |
| Weighted Avg Shares | 2.7M | 3.42M | 4.53M | 5.18M | 10.65M |
| Weighted Avg Shares (Diluted) | 2.7M | 3.42M | 4.53M | 5.18M | 10.65M |
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
Intrinsic Alpha fair value
Locked
Current Price
$3.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.